DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Midostaurin
Midostaurin
FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
Efficacy and Safety of Midostaurin-Based Induction and Maintenance Therapy for Newly Diagnosed AML
Disruption of CSF-1R Signaling Inhibits Growth of AML with Inv(16)
Midostaurin
Recommendations from York and Scarborough Medicines
Samaritan Fund
PRAC Draft Agenda of Meeting 11-14 May 2020
Self-Administered Specialty Drug List
NEW 2018 Specialty Drugs
Simulating Protein–Ligand Binding with Neural Network Potentials
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity
(CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia
View of This Manuscript
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT Beth Apsel Winger1, Wilian A
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Protein Kinase Inhibitors for Acute Leukemia Yuan Ling, Qing Xie, Zikang Zhang and Hua Zhang*
Beyond Midostaurin Which Are the Most Promising FLT3 Inhibitors In
Top View
Ruxolitinib in Combination with Prednisone and Nilotinib Exhibit Synergistic Effects in Human Cells Lines and Primary Cells from Myeloproliferative Neoplasms
FLT3 Inhibition: a Moving and Evolving Target in Acute Myeloid Leukaemia
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
PRAC Draft Agenda of Meeting 23-26 November 2020
Upfront Treatment of FLT3-Mutated AML: a Look Back at the RATIFY Trial and Beyond
NADPH Oxidases Regulate Cell Growth and Migration in Myeloid Cells Transformed by Oncogenic Tyrosine Kinases
CHMP Agenda of the 20-23 July 2020 Meeting
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
PDCO Agenda of the 26-29 January 2021 Meeting
Cardiotoxicity of Novel Targeted Hematological Therapies
Outcomes with Sequential FLT3-Inhibitor-Based Therapies In
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance 2 Profiles in Exon 17-Mutant KIT 3 4 Beth Apsel Wingera, Wilian A
Pharmacy Specialty Drug Policies
Premium Value
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130
Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
Assessment Report
Overview of Current Type I/II Kinase Inhibitors